Details for Patent: 4,895,726
Summary for Patent: 4,895,726
| Title: | Novel dosage form of fenofibrate | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention relates to a novel dosage form of fenofibrate containing fenofibrate and a solid surfactant which have been co-micronized. It also relates to the method for the preparation of this dosage form and its use for improving the bioavailabity in vivo. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Bernard Curtet, Eric Teillaud, Philippe Reginault | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Fournier Industrie et Sante SAS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US07/299,073 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 4,895,726: Fenofibrate Micronization Claims, Scope, Expiration, and Patent LandscapeU.S. Patent 4,895,726 protected a specific fenofibrate formulation technology: co-micronization of fenofibrate with a solid surfactant, principally sodium lauryl sulfate, to produce particles below 15 micrometers and improve oral bioavailability. The patent also covered a manufacturing process, gelatin-capsule dosage forms, and treatment of hyperlipidemia and hypercholesterolemia. The patent issued on January 23, 1990, and expired on January 23, 2007, under the pre-1995 patent term rule of 17 years from issuance. It no longer creates an enforceable patent barrier to generic fenofibrate products.[1] Its historical commercial importance was substantial because it supported micronized 200-mg fenofibrate capsules associated with the original Tricor and related fenofibrate products. What invention does U.S. Patent 4,895,726 protect?The patent protects a formulation in which fenofibrate is not merely micronized alone. The claimed active ingredient is co-micronized with a solid surfactant before the remaining excipients are incorporated. The core technical concept has four elements:
The disclosed purpose is improved dissolution and bioavailability of fenofibrate, a poorly water-soluble lipid-lowering compound. Sodium lauryl sulfate functions as the principal surfactant identified in the claims. The patent therefore targets a formulation and manufacturing platform, not the fenofibrate molecule itself. Fenofibrate was known before the patent and could not be monopolized by this patent as a chemical compound. What are the independent claims of Patent 4,895,726?The patent contains four principal claim categories.
Claims 2 through 7 narrow claim 1. Claims 9, 12 and related dependent claims narrow the manufacturing, bioavailability, or treatment claims. The strongest commercial claim was claim 1 because it captures a finished dosage form. Claim 8 is narrower but potentially relevant to manufacturing operations. Claim 10 focuses on the process used to improve in-vivo bioavailability. Claims 11 and 12 cover treatment with the more specific sodium-lauryl-sulfate formulation and particle-size limits. How should claim 1 be construed?Claim 1 requires more than a capsule containing micronized fenofibrate. Its principal limitations are cumulative. Gelatin capsuleThe product must be presented in gelatin capsules. A tablet, liquid suspension, softgel, or other dosage form would not literally satisfy this limitation unless another claim-construction theory applied. The gelatin-capsule limitation was commercially relevant to early fenofibrate products but reduced the claim's reach against later tablet and reformulated products. Co-micronized mixture"Co-micronized" is the central technical limitation. The claim requires fenofibrate and the solid surfactant to be intimately mixed and micronized together. A product made by:
would present a non-infringement argument because it would lack the claimed co-micronization step or structure. The distinction between co-micronization and post-micronization blending would be important in both infringement analysis and process discovery. Mean particle size below 15 micrometersThe claim uses mean particle size, not a maximum particle size. A product could contain particles above 15 micrometers and still potentially fall within the claim if the measured mean remained below the threshold. Particle-size methodology would therefore matter. Relevant variables include:
Claims 6 and 12 add tighter thresholds of 10 micrometers and 5 micrometers, respectively. Solid surfactantThe surfactant must be solid under the relevant formulation conditions. Claim 4 specifically narrows the composition to sodium lauryl sulfate, also known as sodium dodecyl sulfate. The broadest version of claim 1 is not limited to sodium lauryl sulfate, but the solid surfactant must remain within the claim's formulation and co-micronization architecture. What do the dependent claims add?
Claim 3 is especially relevant to the original product configuration. A later product containing 145 mg or 160 mg fenofibrate would not literally satisfy the 200-mg limitation in claim 3, although it could still implicate broader claims if the other limitations were met. What manufacturing process does claim 8 protect?Claim 8 requires a defined sequence:
This is a process claim with multiple ordered steps. Literal infringement would generally require performance of each claimed step, including the specific excipients and drying endpoint. The claim is narrower than claim 1 because a manufacturer could potentially avoid it by using:
The process claim would have been difficult to enforce against a finished product without access to manufacturing records, batch instructions, or process validation documents. Does Patent 4,895,726 cover fenofibrate itself?No. The patent does not claim fenofibrate as a chemical entity. It covers particular pharmaceutical compositions and processes using fenofibrate. This distinction affects freedom to operate:
When did U.S. Patent 4,895,726 expire?
The expiration date follows the patent term framework applicable when the application was filed. It is not calculated under the 20-year-from-earliest-effective-filing-date rule that applies to most later U.S. applications.[1][2] Any regulatory exclusivity associated with a fenofibrate product would have been separate from this patent term. FDA marketing exclusivity does not revive an expired patent. What was the Orange Book status of Patent 4,895,726?Patent 4,895,726 was historically associated with the original fenofibrate capsule product and was listed in the FDA Orange Book for an approved fenofibrate product. Its listing had commercial significance during the period when generic applicants evaluated abbreviated new drug application, or ANDA, certification requirements.[3] The patent is now expired and does not create a current Orange Book patent barrier. A historical Orange Book listing should not be interpreted as evidence that the patent remains enforceable. For current regulatory analysis, the relevant questions are:
Because fenofibrate is a small-molecule drug, biosimilar analysis does not apply. Generic applicants use the ANDA framework, not the biosimilar pathway under the Public Health Service Act. Were there Paragraph IV challenges to the fenofibrate patent estate?Fenofibrate generic competition involved ANDA litigation and Paragraph IV certifications directed at patents covering Tricor and later fenofibrate formulations. The competitive disputes did not depend solely on Patent 4,895,726. Later fenofibrate products used different strengths, dosage forms, particle technologies, and formulation approaches. The legal significance of a Paragraph IV certification is product-specific. An ANDA applicant could assert that:
Patent 4,895,726 is no longer a practical Paragraph IV obstacle because its term ended in 2007. Later patents had to be assessed separately for products such as 48-mg, 145-mg, 160-mg, and 200-mg fenofibrate presentations. What later patents affected fenofibrate products?The fenofibrate patent estate developed through separate formulation and dosage-form patents after the original micronized-capsule patent. Representative U.S. patents associated with later fenofibrate products include the following:
The exact scope and expiration of each later patent must be evaluated against its claims, prosecution history, term adjustments, terminal disclaimers, and Orange Book listing. A generic product that avoids Patent 4,895,726 may still encounter a later formulation patent. The main commercial transition was from the original 200-mg micronized capsule to lower-dose and reformulated products, including 48-mg and 145-mg presentations. Reformulation allowed sponsors to pursue improved dissolution, dose flexibility, and product differentiation while creating new patent positions. How strong was the patent estate for the original product?The original patent had moderate-to-strong protection for the specific product architecture but limited scope outside it. Strengths
Limitations
Its historical blocking power was therefore strongest against generic versions of the same 200-mg micronized capsule and weakest against materially different dosage forms or processes. What generic launch risks existed?Before expiration, a generic applicant would have faced four principal risks. Product-composition riskA proposed capsule containing co-micronized fenofibrate and a solid surfactant below the claimed particle size could have presented direct infringement risk under claim 1. Process riskA manufacturer using the claimed lactose-starch wet-granulation sequence could have faced process-claim risk under claim 8, even if the finished product's composition was difficult to characterize. Measurement riskA particle-size result below 15 micrometers could support infringement, but the parties would likely dispute analytical methods and batch representativeness. Regulatory-patent riskAn ANDA applicant would have needed to address any listed patent for the reference product through a Paragraph I, II, III, or IV certification. That regulatory issue was separate from the scientific question of whether the product used the claimed formulation. Today, Patent 4,895,726 creates no launch risk because it is expired. Current risk depends on active later patents, regulatory exclusivity, manufacturing know-how, and product-specific Orange Book records. Are there biosimilar risks or manufacturing barriers?There is no biosimilar risk because fenofibrate is a chemically synthesized small molecule. The relevant competition is generic fenofibrate under the ANDA pathway. Manufacturing barriers are lower than patent barriers now. The process requires conventional pharmaceutical operations:
The more difficult technical issues are process reproducibility, particle-size control, dissolution performance, surfactant distribution, and stability. Those issues can affect FDA approval without creating an enforceable monopoly under the expired patent. What licensing deals affected the patent?Laboratoires Fournier was the original patent owner and developer associated with the technology. Fournier's fenofibrate business later became connected with Abbott Laboratories through commercial and corporate transactions involving Tricor and related products. The patent record does not establish a continuing license restriction that survives expiration. Any historical license, assignment, or collaboration involving the patent cannot extend the patent's statutory term. What is the current competitive landscape?The fenofibrate market includes generic products in multiple strengths and dosage forms. Competitive differentiation has centered on:
The original 200-mg capsule technology remains important as a historical reference point, but current market access is governed by generic approvals and any surviving later formulation patents rather than Patent 4,895,726. Key Takeaways
FAQsDoes Patent 4,895,726 cover all micronized fenofibrate products?No. It targets co-micronized fenofibrate and solid surfactant in the claimed particle-size range, with additional dosage-form and formulation limitations. It does not claim all micronized fenofibrate. Can a tablet infringe Patent 4,895,726?A tablet would have a strong non-infringement position against claims requiring a gelatin capsule. It could still raise separate issues under a different patent estate, particularly patents directed to later tablet formulations. Is sodium lauryl sulfate required by every claim?No. Claim 1 broadly recites a solid surfactant. Claims 4, 5, 6 and 9 specifically narrow the invention to sodium lauryl sulfate. Does a 145-mg fenofibrate product fall within claim 3?No, not literally. Claim 3 requires 200 mg of fenofibrate per therapeutic unit. A 145-mg product could still require analysis under broader claims or later patents. What patent protects generic fenofibrate today?Patent 4,895,726 protects none because it expired in 2007. Any current patent issue must be evaluated against the specific fenofibrate product, dosage form, formulation, Orange Book listing, and active later patents. References
More… ↓ |
Drugs Protected by US Patent 4,895,726
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 4,895,726
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| France | 88 02359 | Feb 26, 1988 |
International Family Members for US Patent 4,895,726
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 83374 | ⤷ Start Trial | |||
| Australia | 2982889 | ⤷ Start Trial | |||
| Australia | 614577 | ⤷ Start Trial | |||
| Canada | 1322529 | ⤷ Start Trial | |||
| Germany | 68903846 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
